EKTA.B

48.94

+0.2%↑

EKTA.B

48.94

+0.2%↑

EKTA.B

48.94

+0.2%↑

EKTA.B

48.94

+0.2%↑

EKTA.B

48.94

+0.2%↑

Search

Vivesto AB

Slēgts

0

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

Galvenie mērījumi

By Trading Economics

Ienākumi

-1.2M

-9.5M

EPS

-0.018

Darbinieki

4

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 11. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-1.1M

129M

Iepriekšējā atvēršanas cena

0

Iepriekšējā slēgšanas cena

0

Vivesto AB Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 7. okt. 16:58 UTC

Peļņas

BMW Trims 2025 View, Citing Weaker Performance in China

2025. g. 7. okt. 23:43 UTC

Tirgus saruna

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

2025. g. 7. okt. 23:36 UTC

Tirgus saruna

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

2025. g. 7. okt. 23:19 UTC

Tirgus saruna

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

2025. g. 7. okt. 22:50 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 7. okt. 22:50 UTC

Tirgus saruna

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

2025. g. 7. okt. 22:40 UTC

Tirgus saruna

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

2025. g. 7. okt. 21:56 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 7. okt. 21:56 UTC

Tirgus saruna

Australia Shares Set to Start Day Roughly Flat -- Market Talk

2025. g. 7. okt. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 7. okt. 20:44 UTC

Karstas akcijas

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

2025. g. 7. okt. 19:42 UTC

Tirgus saruna

Treasury Yields Fall as Data Blackout Continues -- Market Talk

2025. g. 7. okt. 19:23 UTC

Iegādes, apvienošanās, pārņemšana

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

2025. g. 7. okt. 19:07 UTC

Tirgus saruna

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

2025. g. 7. okt. 19:02 UTC

Tirgus saruna

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

2025. g. 7. okt. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 7. okt. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 7. okt. 16:20 UTC

Tirgus saruna

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

2025. g. 7. okt. 16:15 UTC

Tirgus saruna

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

2025. g. 7. okt. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 7. okt. 15:37 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 7. okt. 15:37 UTC

Tirgus saruna

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

2025. g. 7. okt. 15:33 UTC

Tirgus saruna

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

2025. g. 7. okt. 15:25 UTC

Tirgus saruna

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

2025. g. 7. okt. 15:15 UTC

Tirgus saruna

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

2025. g. 7. okt. 15:04 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 7. okt. 15:04 UTC

Tirgus saruna

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

2025. g. 7. okt. 14:56 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 7. okt. 14:56 UTC

Tirgus saruna

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

2025. g. 7. okt. 14:52 UTC

Peļņas

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Vivesto AB Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
help-icon Live chat